The pioneer in the use of AI algorithms and machine learning, Viz.ai is increasing the speed of diagnosis and care for more than 220 million patients across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies patients with particular diseases, informs critical decisions at the point of care, and optimizes care pathways to help improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies.
Harnessing AI to close the gaps between patients, clinicians, and life-saving treatments
Viz.ai has developed a suite of AI-powered solutions that can analyze patient CT, CTA, MRI, and ECG data in real time, 24/7, and alert care teams of suspected conditions within minutes. On-call care teams can use Viz.ai’s HIPAA-compliant mobile and web interface to review flagged, high-fidelity images in 3D on a phone, computer or radiology workstation and consult with colleagues. After confirming diagnosis, clinicians can also use the Viz platform to share the patient’s imaging data and coordinate with the entire care team, to quickly facilitate patient triage. As a result, Viz.ai is closing the gaps between patients, clinicians, and life-saving treatments.
On the Viz.ai platform, there are 9 FDA-cleared algorithms and care pathways across neurovascular and cardiac conditions that detect blockages, impending ruptures or bleeds in the brain, lungs, or aorta: cerebral aneurysms, subdural hematomas, intracranial hemorrhages, pulmonary embolisms, aortic disease, and large vessel occlusion strokes.
In March 2023, Viz AAA also became the first FDA-cleared, AI-powered solution for the detection and triage of suspected abdominal aortic aneurysm (AAA). This advance is particularly important because there are an estimated 1.1 million Americans living with an AAA, most of whom are asymptomatic and unaware of their condition until a rupture occurs. Being able to identify suspected AAAs earlier has life-saving implications.
Clinical Trial Adoption
Viz.ai is now also playing an active role in optimizing patient recruitment for life science clinical trials. Use of its AI-powered clinical research platform, Viz RECRUIT, has demonstrated a three-fold acceleration in participant enrollment.
In February 2023, the platform was chosen by the BIOS Clinical Trials Coordinating Center at Johns Hopkins University to expedite patient enrollment in its National Institute of Health (NIH)-funded Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) study. As Viz RECRUIT can identify trial-eligible patients by scanning their images in real-time, it enables 24/7 automatic identification of potential study participants and sends immediate notifications to the research team.
In March 2023, Viz RECRUIT was selected to identify, screen, and enroll patients in the NIH-funded Pulmonary Embolism—Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial. PE-TRACT is a randomized controlled clinical trial that will examine whether catheter therapy should be routinely used to treat intermediate-risk pulmonary embolism versus anticoagulants alone. Investigators plan to enroll 500 patients across 30-50 sites.
About Digital Health Innovation Summit 2023
Join World BI for its 23rd rebranded edition of the Digital Health Innovation Summit – a unique opportunity to connect with thought leaders from the pharma, healthcare, and medtech industries, while learning about the newest trends in digital health technologies and clinical trial innovation.
This new conference provides you with industry recommendations, case studies, and the actionable insights you need to transform your own projects and strategically bring it to the next level through scientific discovery, collaborative research, medtech entrepreneurship, and pharma-tech partnerships.
Join us to learn from the best in the drug development industry, including clinicians, scientists, entrepreneurs, biomedical engineers, patient advocates, and top technology providers across the globe. And if that’s not enough, the conference will be held at the Hyatt Regency San Francisco Embarcadero Waterfront Hotel.